Updates on Dengue Vaccine and Antiviral: Where Are We Heading?

Approximately 100–400 million people from more than 100 countries in the tropical and subtropical world are affected by dengue infections. Recent scientific breakthroughs have brought new insights into novel strategies for the production of dengue antivirals and vaccines. The search for specific den...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Harun Norshidah, Ramachandran Vignesh, Ngit Shin Lai
Format:	article
Langue:	EN
Publié:	MDPI AG 2021
Sujets:	dengue virus NS2B/NS3pro antiviral drug discovery vaccine Organic chemistry QD241-441
Accès en ligne:	https://doaj.org/article/dc66ccf0fba94e56aa7bec795ec99b09
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:dc66ccf0fba94e56aa7bec795ec99b09
record_format	dspace
spelling	oai:doaj.org-article:dc66ccf0fba94e56aa7bec795ec99b092021-11-25T18:27:06ZUpdates on Dengue Vaccine and Antiviral: Where Are We Heading?10.3390/molecules262267681420-3049https://doaj.org/article/dc66ccf0fba94e56aa7bec795ec99b092021-11-01T00:00:00Zhttps://www.mdpi.com/1420-3049/26/22/6768https://doaj.org/toc/1420-3049Approximately 100–400 million people from more than 100 countries in the tropical and subtropical world are affected by dengue infections. Recent scientific breakthroughs have brought new insights into novel strategies for the production of dengue antivirals and vaccines. The search for specific dengue inhibitors is expanding, and the mechanisms for evaluating the efficacy of novel drugs are currently established, allowing for expedited translation into human trials. Furthermore, in the aftermath of the only FDA-approved vaccine, Dengvaxia, a safer and more effective dengue vaccine candidate is making its way through the clinical trials. Until an effective antiviral therapy and licensed vaccine are available, disease monitoring and vector population control will be the mainstays of dengue prevention. In this article, we highlighted recent advances made in the perspectives of efforts made recently, in dengue vaccine development and dengue antiviral drug.Harun NorshidahRamachandran VigneshNgit Shin LaiMDPI AGarticledengue virusNS2B/NS3proantiviraldrug discoveryvaccineOrganic chemistryQD241-441ENMolecules, Vol 26, Iss 6768, p 6768 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	dengue virus NS2B/NS3pro antiviral drug discovery vaccine Organic chemistry QD241-441
spellingShingle	dengue virus NS2B/NS3pro antiviral drug discovery vaccine Organic chemistry QD241-441 Harun Norshidah Ramachandran Vignesh Ngit Shin Lai Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
description	Approximately 100–400 million people from more than 100 countries in the tropical and subtropical world are affected by dengue infections. Recent scientific breakthroughs have brought new insights into novel strategies for the production of dengue antivirals and vaccines. The search for specific dengue inhibitors is expanding, and the mechanisms for evaluating the efficacy of novel drugs are currently established, allowing for expedited translation into human trials. Furthermore, in the aftermath of the only FDA-approved vaccine, Dengvaxia, a safer and more effective dengue vaccine candidate is making its way through the clinical trials. Until an effective antiviral therapy and licensed vaccine are available, disease monitoring and vector population control will be the mainstays of dengue prevention. In this article, we highlighted recent advances made in the perspectives of efforts made recently, in dengue vaccine development and dengue antiviral drug.
format	article
author	Harun Norshidah Ramachandran Vignesh Ngit Shin Lai
author_facet	Harun Norshidah Ramachandran Vignesh Ngit Shin Lai
author_sort	Harun Norshidah
title	Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
title_short	Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
title_full	Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
title_fullStr	Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
title_full_unstemmed	Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
title_sort	updates on dengue vaccine and antiviral: where are we heading?
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/dc66ccf0fba94e56aa7bec795ec99b09
work_keys_str_mv	AT harunnorshidah updatesondenguevaccineandantiviralwhereareweheading AT ramachandranvignesh updatesondenguevaccineandantiviralwhereareweheading AT ngitshinlai updatesondenguevaccineandantiviralwhereareweheading
_version_	1718411163669102592

Updates on Dengue Vaccine and Antiviral: Where Are We Heading?

Documents similaires